INTRODUCTION {#s1}
============

Ovarian cancer is the fifth leading cause of cancer-related death in women around the world. It is estimated that 1,4240 deaths will be attributed to this disease according to the National Cancer Institute \[[@R1]\]. As early-stage ovarian cancer is typically asymptomatic, most patients are diagnosed at more advanced stages, with associated dismal prognosis.

Traditionally, lymph node status has been considered to be an important predictor of outcomes for patients with ovarian cancer \[[@R2], [@R3]\]. Presently, lymph node status is based on PLNs regardless of the number of resected lymph node (RLNs) in epithelial ovarian cancer (EOC) patient \[[@R4], [@R5]\]. Consequently, the actual lymph node status may not adequately be reflected by the number of positive lymph node (PLNs).

Recently, ratio of PLNs to RLNs (LNR) and log of odds between PLNs and the number of negative lymph node (LODDS) have emerged as alternative predictive factors for outcomes in breast \[[@R6], [@R7]\], gastric \[[@R8]\], pancreatic \[[@R9]\] and colorectal cancer \[[@R10], [@R11]\]. LNR is defined as the ratio of PLNs to RLNs. This parameter showed superiority to the lymph node status-based assessment system of N stage in several cancers, such as breast \[[@R6], [@R12]\], gastric \[[@R8]\], and colon cancer \[[@R13], [@R14]\]. LNR was also studied in ovarian cancer and found to be superior to both PLN and RLN number in predicting survival \[[@R15], [@R16]\].

LODDS is defined as the log of odds between PLNs and the number of negative node. While this parameter has been validated in predicting survival for breast cancer, its utility in epithelial ovarian cancer is unknown \[[@R7], [@R17], [@R18]\]. We hypothesized that LODDS might be an important predictor of outcomes in epithelial ovarian cancer and that a nomogram incorporating LODDS may be superior in this respect to the currently-utilized FIGO score.

RESULTS {#s2}
=======

Clinical characteristics {#s2_1}
------------------------

The clinicopathological characteristics of these patients are listed in Table [1](#T1){ref-type="table"}. There were no significant differences between the training and validation cohorts. The median age at the time of diagnosis was 7 (49--66) years in both cohorts. Most patients are married (56.8%). The majority of patients were Stage III at the time of surgery (47.5%). The most frequent histologic type was serous (56.5%). A majority of patients (98.8%) did not receive radiotherapy. The mean values for RLNs, PLNs, LNR and LODDS were 14.37, 1.35, 0.13 and -0.99 respectively. Additionally, the median survival time was 38 (90--145) months.

###### Clinicopathological characteristics of EOC patients in the training and validation cohort

  Characteristic                All patients (*n* =10692)   Training cohort (*n* = 7021)   Validation cohort (*n* = 3671)   P
  ----------------------------- --------------------------- ------------------------------ -------------------------------- ------
  **Age at diagnosis, years**                                                                                               0.63
   Median (IQR)                 57(49-66)                   57(49-66)                      57(49-66)                        
  **Year of diagnosis**                                                                                                     0.56
   2004-2007                    3936                        2559                           1377                             
   2007-2010                    3261                        2152                           1109                             
   2010-2013                    3495                        2310                           1185                             
  **Race**                                                                                                                  0.17
   White                        9045                        5906                           3139                             
   Black                        521                         354                            167                              
   Other\*                      1126                        761                            365                              
  **Marital status**                                                                                                        0.04
   Married                      6069                        4042                           2027                             
   Single                       2085                        1360                           725                              
   Others\#                     2538                        1619                           919                              
  **FIGO Stage**                                                                                                            0.78
   I                            4172                        2745                           1427                             
   II                           1445                        937                            508                              
   III                          5075                        3339                           1736                             
  **Grade**                                                                                                                 0.13
   Well differentiate           1592                        1051                           541                              
   Moderately differentiate     2482                        1581                           901                              
   Poor differentiate           4482                        2979                           1503                             
  **Tumor location**                                                                                                        
   One site                     6738                        4427                           2311                             0.87
   Bilateral site               3859                        2534                           1325                             
   Paired site                  95                          60                             35                               
  **Radiation**                                                                                                             
   No                           10565                       6935                           3630                             0.70
   Yes                          127                         86                             41                               
  **Histology**                                                                                                             0.98
   Serous                       6037                        3977                           2060                             
   Mucinous                     1022                        669                            353                              
   Endometrioid                 2518                        1642                           876                              
   Clear cell                   1054                        692                            362                              
   Undifferentiated             61                          41                             20                               
  **RLNs**                                                                                                                  0.76
   Mean (range)                 14.37(1-90)                 14.45(1-90)                    14.23(1-90)                      
  **PLNs**                                                                                                                  0.77
   Mean (range)                 1.35(0-90)                  1.39(0-90)                     1.26(0-57)                       
  **LNR**                                                                                                                   0.72
   Mean (range)                 0.13(0.00-1.00)             0.13(0.00-1.00)                0.13(1.00-1.00)                  
  **LODDS**                                                                                                                 0.86
   Mean (range)                 −0.99(-2.26-2.26)           −0.98(-2.26-2.26)              −0.99(-2.16-1.95)                

Other including American Indian/AK Native, Asian/Pacific Islander.

Other including Widowed, Divorced, Separated and unknown

Poor differentiate including Poor differentiate and undifferentiated

Abbreviations: RLNs, the number of lymph node examined; PLNs, the number of positive lymph node; LNR, positive lymph node ratio; LODDS, log of odds between the number of PLNs and number of negative nodes.

Factors associated with OS {#s2_2}
--------------------------

Age at diagnosis, race, marital status, year of diagnosis, tumor location, tumor stage, tumor grade, histology, RLNs, PLNs, LNR, LODDS and treatment with radiation therapy were evaluated. All variables were significantly correlated with OS in univariate survival analysis (P \< 0.05). Independent prognostic factors associated with OS identified from the multivariate analysis were subsequently incorporated into the nomogram (Table [2](#T2){ref-type="table"}).

###### Characteristics and multivariate analysis in the training set

  Variables                 Univariate Analysis   Multivariate Analysis                         
  ------------------------- --------------------- ----------------------- --------------------- ---------
  Age at diagnosis, years   1.04(1.03-1.04)       \<.001                  1.028(1.024-1.032)    \<.001
  Race                      0.90(0.84-0.97)       0.01                                          
   Other\*                                                                Reference             
   White                                                                  1.106(0.934-1.311)    0.242
   Black                                                                  1.427(1.118-1.820)    0.004
  Marital status            1.19(1.13-1.26)       \<.001                                        
   Others^\#^                                                             Reference             
   Married                                                                0.818(0.734-0.911)    \<.001
   Single                                                                 0.907(0.780-1.053)    0.200
  Stage                     2.46(2.30-2.62)       \<.001                                        
   III                                                                    Reference             
   I                                                                      0.280(0.238-0.330)    \<.001
   II                                                                     0.469(0.395-0.557)    \<.001
  Grade                     1.52(1.45-1.60)       \<.001                                        
   Poor differentiate                                                     Reference             
   Well differentiate                                                     0.514(0.412-0.642)    .000
   Mediate differentiate                                                  0.845(0.744- 0.961)   .010
  Tumor location            1.45(1.39-1.51)       \<.001                                        
   Paired site                                                            Reference             
   One site                                                               0.897(0.591-1.361)    0.609
   Bilateral site                                                         1.154(0.762- 1.747)   0.500
  Radiation                 1.45(1.04-2.00)       0.03                                          
   No                                                                                           
   Yes                                                                                          
  Histology                 0.68(0.65-0.72)       \<.001                                        
   Undifferentiated                                                       Reference             
   Serous                                                                 0.686(0.421-1.118)    0.131
   Mucinous                                                               1.193(0.701 -2.031)   0.515
   Endometrioid                                                           0.613(0.3691-.019)    0.059
   Clear cell                                                             0.983(0.587-1.647)    0.949
  RLNs                      0.98(0.98-0.99)       \<.001                  0.995(0.991-0.999)    0.013
  PLNs                      1.04(1.04-1.05)                                                     
  LNR                       4.67(4.15-5.27)                                                     
  LODDS                     2.10(1.99-2.21)                               1.359(1.269-1.454)    \<0.001

Other including American Indian/AK Native, Asian/Pacific Islander.

Other including Widowed, Divorced, Separated and unknown.

Poor differentiate including Poor differentiate and undifferentiated.

Abbreviations: CI, confidence interval; HR, hazard ratio; RLNs, the number of lymph node examined; PLNs, the number of positive lymph node; LNR, positive lymph node ratio; LODDS, log of odds between the number of PLNs and number of negative nodes.

Comparing the prognostic impact of RLNs, PLNs, LNR and LODDS {#s2_3}
------------------------------------------------------------

According to Figure [1](#F1){ref-type="fig"}, it is clearly that LODDS is a prognostic factor for EOC patients. The AUCs corresponding to inclusion of RLNs, PLNs, LNR and LODDS were 0.602, 0.625, 0.635 and 0.683 (respectively) for predicting OS and 0.590, 0.638, 0.646 and 0.686 (respectively) for predicting CSS (Figure [2](#F2){ref-type="fig"}), suggesting that LODDS may have superior discriminatory ability in predicting OS and CSS than the other parameters

![Comparison of the areas under curves of the number of RLNs, PLNs, LNR and LODDS to predict the impact of these factors on OS **A.** and CSS **B.** in the SEER training cohort. The green lines represent LODDS predicted survival, the blue lines represent the LNR predicted survival, the red line represent PLNs predicted survival and the black line represent RLNs predicted survival. Abbreviation: OS, overall survival; CSS, cancer specific survival; RLNs, the number of resected lymph node; PLNs, the number of positive lymph node; LNR, ratio of PLNs to RLNs; LODDS, log of odds between the number of positive lymph node (PLNs) and number of negative nodes.](oncotarget-08-8120-g001){#F1}

![The overall survival (OS) and cancer specific survival (CSS) curves of epithelial ovarian cancer patients according to the cutoff points based on LODDS. OS **A.** and CSS **B.** are plotted using the Kaplan-Meier method and analyzed by the log-rank test (P\<0.001). Abbreviation: OS, overall survival; CSS, cancer specific survival; LODDS, log of odds between the number of positive lymph node (PLNs) and number of negative nodes.](oncotarget-08-8120-g002){#F2}

Nomogram {#s2_4}
--------

All of the 11 parameters were associated with overall survival analyzed in the univariate analysis in EOC patients (Table [2, P](#T2){ref-type="table"} \< 0.05). Nomograms for predicting 3- and 5 year OS and CSS were constructed based on the multivariate models by the backward method in the training cohort (Figure [3](#F3){ref-type="fig"}). By summing and locating the scores on the total score scale, the estimated probability of cancer-specific survival at 3- and 5-years could be determined. The bootstrap-corrected concordance indices were 0.75 (95% CI, 0.74-0.77) for predicting OS and 0.77 (95% CI, 0.76-0.78) for predicting CSS. Notably, the C-indices for FIGO stage were significantly lower: 0.699 (95% CI, 0.688-0.710, P \< 0.05) for predicting OS and 0.719 (95% CI, 0.709- 0.730, P \< 0.05) for predicting CSS.

![Nomogram for predicting 3- and 5-year **A.** cancer specific survival (CSS) and **B.** overall survival (OS) of epithelial ovarian cancer patients. To use of the nomogram, you should assign the points of each characteristic of the patient by drawing a vertical line from that variable to the point scale, sum all the points and draw a vertical line from the total points scale to the 3- and 5-year CSS or OS to obtain the probability of death. Abbreviation: OS, overall survival; CSS, cancer specific survival; LODDS, log of odds between the number of positive lymph node (PLNs) and number of negative nodes.](oncotarget-08-8120-g003){#F3}

Validation for nomogram {#s2_5}
-----------------------

Validation of the nomogram was performed by 1000 bootstrap. In the training cohort, the Harrell\'s C-indices for the nomogram to predict OS and CSS were 0.757 (95% CI, 0.746-0.768) and 0.770 (95% CI, 0.759-0.782), respectively. Similarly, in the validation cohort, the C-indices to predict OS and CSS were 0.757 (95% CI, 0.741-0.773) and 0.762 (95% CI, 0.746-0.779). This finding implied that this model was reasonably accurate. The calibration plots demonstrated excellent correlation between predicted and observed values of OS and CSS in both training and validation cohorts (Figure [4](#F4){ref-type="fig"} & Figure [5](#F5){ref-type="fig"}). Moreover, when comparing the c-index for OS and CSS based on either nomogram or FIGO stage, our nomogram showed better predictive probability than FIGO stage (Figure [6](#F6){ref-type="fig"}).

![The calibration plots predicting overall survival **A-B.** and cancer specific survival **C-D.** at 3- and 5-year point in the training cohort. The dashed line represents a perfect match between the nomogram predicted probability (x-axis) and the actual probability calculated by Kaplan-Meier analysis (y-axis). Abbreviation: OS, overall survival; CSS, cancer specific survival.](oncotarget-08-8120-g004){#F4}

![The calibration plots predicting overall survival A-B. and cancer specific survival C-D. at 3- and 5-year point in the validation cohort. The dashed line represents a perfect match between the nomogram predicted probability (x-axis) and the actual probability calculated by Kaplan-Meier analysis (y-axis). Abbreviation: OS, overall survival; CSS, cancer specific survival.](oncotarget-08-8120-g005){#F5}

![Comparison of the areas under curves of nomogram and Stage to prediction of OS **A, C.** and CSS **B, D.** in the training (A, B) and validation cohort (C, D). The red lines represent nomogram predicted survival and the black lines represent the traditional stage predicted survival. Abbreviation: OS, overall survival; CSS, cancer specific survival.](oncotarget-08-8120-g006){#F6}

DISCUSSION {#s3}
==========

In this study, a novel nomogram based on LODDS was developed and validated to predict post-operative outcomes in epithelial ovarian cancer. In training and validation cohorts that were randomly extracted from the SEER database, this nomogram appears to predict OS and CSS more accurately than the currently utilized FIGO staging system.

A nomogram is a convenient tool for quantifying risk by incorporating and illustrating the relative importance of various prognostic factors and has been widely used in clinical oncology \[[@R19]\]. Several nomograms have been constructed to date to predict outcomes in ovarian cancer patients \[[@R20]--[@R23]\]. To our knowledge, however, a nomogram based on LODDS for predicting outcomes in epithelial ovarian cancer patients has not been described.

It is well known that lymph node status can be used for post-operative risk stratification in epithelial ovarian cancer patients. The currently-utilized FIGO staging system uses PLNs in this calculus \[[@R4]\]. PLNs, however, remain a function of RLNs, and may not adequately reflect disease status in all situations \[[@R24]\]. For this reason, it is intuitive that RLNs and the number of negative lymph nodes should be simultaneously taken into consideration when formulating an adjuvant treatment plan. LODDS is an intuitive indicator that is reflective of both interrogated lymph nodes and the number of negative lymph nodes, and its use is supported by available data in other malignancies \[[@R7], [@R9]--[@R11]\]. For the first time in the epithelial ovarian cancer population, we evaluated ROC curves based on RLNs, PLNs, LNR and LODDS, and found that LODDS has the highest AUC with superior sensitivity and specificity compared to other factors.

We subsequently constructed a nomogram where patients were randomly assigned to either training or validation cohorts to avoid selection bias.

To date, several nomograms have been constructed for predicting outcomes in EOC patients that possess superior predictive ability compared to the widely-utilized FIGO staging system. In 2012, Barlin and colleagues evaluated for parameters predicting disease-specific survival after surgery based on outcomes in 478 EOC patients \[[@R25]\]. Lee et al. evaluated parameters predicting survival in patients initially responsive to a platinum-based regimen subsequently demonstrating recurrent disease in 2013 \[[@R26]\]. More recent studies evaluated survival based on surgery type \[[@R22], [@R23]\].

However, all of these nomograms were based on very limited cases. Thus, it is unclear whether it can be generally applied. Actually, sufficient data included is useful to improve the accuracy of nomogram. Compared with previous nomogram, our nomogram was developed and validated based both on a larger population on seer database which included several departments and racial might be universally applied.

The C-indexes for the nomograms to predict OS and CSS were 0.757, 0.770 respectively in the training cohort and 0.74, 0.76 respectively in the validation cohort which higher than FIGO stage. Therefore, this nomogram model has less bias and better accuracy when applied in practical work.

Improving the accuracy of the survival estimation is exceedingly important for clinical decision. Several advantages can be obtained by using nomogram. Firstly, as our nomogram performed better than FIGO stage on prediction of individual survival, it would be useful for designing postoperative treatment and the probability of excessive treatment would be reduced. Secondly, because our nomogram could calculate 3--year and 5--year survival rate individually, a more reasonable follow--up schedule could be obtained. Thirdly, individual consultant is in need of nomogram. The survival of EOC could not be accurately predicted by FIGO stage. In comparison, our nomogram can provide individualized estimation for EOC cancer patients.

Although the nomogram model demonstrated good accuracy for predicting OS and CSS, there are several limitations to the data which must be considered. Firstly, this study based on retrospective data which has inevitable inherent bias. Secondly, some prognostic factors like chemotherapy data and tumor marker like CA-125 which were not available. Finally, external validation should be carried out. In summary, our study demonstrated that LODDS was independently associated with the prognosis of EOC patients. We developed and validated a nomogram based on LODDS to estimate 3- and 5-year OS and CSS among EOC which could successfully stratify patients according to their OS and CSS. This clinically useful tool uses available clinicopathologic factors to estimate the probability of OS and CSS, which can further contribute to the individualized clinical decision.

MATERIALS AND METHODS {#s4}
=====================

Data were collected from the SEER program of the National Cancer Institute consisting of 18 population based cancer registries, which covers approximately 28% of the US population (<http://seer.cancer.gov/>). All pathologically-confirmed and surgically-treated EOC patients from the SEER database between 2004 and 2013 were included. Patients with unknown or incomplete lymph node status were excluded. A total of 10,692 patients with histologically confirmed EOC were obtained. These cases were then randomized to two groups (training cohort, N=7,021 and validation cohort, N=3,671). Patients in American Indian/Alaskan Native and Asian/Pacific Islanders were recorded as "other" under race. Widowed, Divorced, Separated and unknown were recorded as "other" under marital status. Poor differentiate and undifferentiated were classified as the poor differentiate group.

Our study was approved by Ethical Committee of Sun Yat-Sen University Cancer Center. Cancer is a reportable disease in every state in the US, informed patient consent is not required for the data released by the SEER database.

Statistical analysis {#s4_1}
--------------------

Construction of the nomogram {#s4_2}
----------------------------

Eligible patients were randomly divided into training (n = 7,021) and validation cohorts (n= 3,671) to establish and validate the nomogram. The follow-up time was defined as the time between the surgery and the last follow-up time. OS was defined as the time between the surgery and cancer-specific death or the last follow-up time. CSS was defined as the time between the surgery and cancer-specific death. The Kaplan-Meier method and Cox regression analysis were used to determine factors associated with survival. Significant factors were used to construct the nomogram for OS and CSS.

Validation of the nomogram {#s4_3}
--------------------------

1000 bootstrap were performed for validation. Calibration diagrams were created with the marginal estimate versus model average predictive probability. The predictions should fall on a 45-degree diagonal line in a perfectly calibrated model. An index of probability of concordance (C-index) between predicted probability and actual outcome was calculated to evaluate the predicting ability and discrimination of the model \[[@R27]\]. The value of the C-index ranges from 0.5 to 1.0, with 0.5 indicating random chance and 1.0 indicating a perfectly corrected discrimination.

Statistical analysis was performed using SPSS 19.0 (SPSS, Chicago, IL, USA) and R version 3.3.0 software (Institute for Statistics and Mathematics, Vienna, Austria;[www.r-project.org](http://www.r-project.org)). The "rms" R library by Harrell ([cran.r-project.org/web/packages/rms](http://cran.r-project.org/web/packages/rms)) was used to construct survival models \[[@R28]\]. P value less than 0.05 were considered statistically significant.
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